Discovering the Interactome, Functions, and Clinical Relevance of Enhancer RNAs in Kidney Renal Clear Cell Carcinoma

Overview

Journal BMC Med Genomics

Publisher Biomed Central

Specialty Genetics

Date 2025 Jan 3

PMID 39754187

Authors

Zhaohui Sun

Haojie Du

Xudong Zheng

Hepeng Zhang

Huajie Hu

Affiliations

Soon will be listed here.

Abstract

Enhancer RNA (eRNA) has emerged as a key player in cancer biology, influencing various aspects of tumor development and progression. In this study, we investigated the role of eRNAs in kidney renal clear cell carcinoma (KIRC), the most common subtype of renal cell carcinoma. Leveraging high-throughput sequencing data and bioinformatics analysis, we identified differentially expressed eRNAs in KIRC and constructed eRNA-centric regulatory networks. Our findings revealed that up-regulated eRNAs in KIRC potentially regulate immune response and hypoxia pathways, while down-regulated eRNAs may impact ion transport, cell cycle, and metabolism. Furthermore, we developed a diagnostic prediction model based on eRNA expression profiles, demonstrating its effectiveness in KIRC diagnosis. Finally, we elucidated the regulatory mechanism of an eRNA (ENSR00000305834) on the expression of SLC15A2, a potential prognostic biomarker in KIRC, through bioinformatics analysis and in vitro validation experiments. In summary, Our study highlights the clinical significance of eRNAs in KIRC and underscores their potential as therapeutic targets.

References

Hu Y, Song F, Jiang H, Nunez G, Smith D . SLC15A2 and SLC15A4 Mediate the Transport of Bacterially Derived Di/Tripeptides To Enhance the Nucleotide-Binding Oligomerization Domain-Dependent Immune Response in Mouse Bone Marrow-Derived Macrophages. J Immunol. 2018; 201(2):652-662. PMC: 6039277. DOI: 10.4049/jimmunol.1800210. View

Lee J, Xiong F, Li W . Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential. RNA Biol. 2020; 17(11):1550-1559. PMC: 7567500. DOI: 10.1080/15476286.2020.1712895. View

Vaupel P, Multhoff G . Hypoxia-/HIF-1α-Driven Factors of the Tumor Microenvironment Impeding Antitumor Immune Responses and Promoting Malignant Progression. Adv Exp Med Biol. 2018; 1072:171-175. DOI: 10.1007/978-3-319-91287-5_27. View

Smith D, Clemencon B, Hediger M . Proton-coupled oligopeptide transporter family SLC15: physiological, pharmacological and pathological implications. Mol Aspects Med. 2013; 34(2-3):323-36. PMC: 3602806. DOI: 10.1016/j.mam.2012.11.003. View

Jiang H, Chen H, Wan P, Song S, Chen N . Downregulation of enhancer RNA EMX2OS is associated with poor prognosis in kidney renal clear cell carcinoma. Aging (Albany NY). 2020; 12(24):25865-25877. PMC: 7803531. DOI: 10.18632/aging.202151. View

Jeong M, Goodell M . Noncoding Regulatory RNAs in Hematopoiesis. Curr Top Dev Biol. 2016; 118:245-70. DOI: 10.1016/bs.ctdb.2016.01.006. View

Alchahin A, Mei S, Tsea I, Hirz T, Kfoury Y, Dahl D . A transcriptional metastatic signature predicts survival in clear cell renal cell carcinoma. Nat Commun. 2022; 13(1):5747. PMC: 9525645. DOI: 10.1038/s41467-022-33375-w. View

Zhang Y, Gong L, Ding R, Chen W, Rong H, Li Y . eRNA-IDO: A One-stop Platform for Identification, Interactome Discovery, and Functional Annotation of Enhancer RNAs. Genomics Proteomics Bioinformatics. 2024; 22(4). PMC: 11514848. DOI: 10.1093/gpbjnl/qzae059. View

Rankin E, Giaccia A . The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; 15(4):678-85. PMC: 3050610. DOI: 10.1038/cdd.2008.21. View

10.

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

11.

Schmitt A, Hu M, Ren B . Genome-wide mapping and analysis of chromosome architecture. Nat Rev Mol Cell Biol. 2016; 17(12):743-755. PMC: 5763923. DOI: 10.1038/nrm.2016.104. View

12.

Zeng W, Liu Q, Yin Q, Jiang R, Wong W . HiChIPdb: a comprehensive database of HiChIP regulatory interactions. Nucleic Acids Res. 2022; 51(D1):D159-D166. PMC: 9825415. DOI: 10.1093/nar/gkac859. View

13.

Andersson R, Gebhard C, Miguel-Escalada I, Hoof I, Bornholdt J, Boyd M . An atlas of active enhancers across human cell types and tissues. Nature. 2014; 507(7493):455-461. PMC: 5215096. DOI: 10.1038/nature12787. View

14.

Rubio-Aliaga I, Frey I, Boll M, Groneberg D, Eichinger H, Balling R . Targeted disruption of the peptide transporter Pept2 gene in mice defines its physiological role in the kidney. Mol Cell Biol. 2003; 23(9):3247-52. PMC: 153205. DOI: 10.1128/MCB.23.9.3247-3252.2003. View

15.

Liu W, Liang R, Ramamoorthy S, Fei Y, Ganapathy M, Hediger M . Molecular cloning of PEPT 2, a new member of the H+/peptide cotransporter family, from human kidney. Biochim Biophys Acta. 1995; 1235(2):461-6. DOI: 10.1016/0005-2736(95)80036-f. View

16.

Ji F, Zhang F, Zhang M, Long K, Xia M, Lu F . Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway. J Hematol Oncol. 2021; 14(1):152. PMC: 8461872. DOI: 10.1186/s13045-021-01168-1. View

17.

Han Z, Li W . Enhancer RNA: What we know and what we can achieve. Cell Prolif. 2022; 55(4):e13202. PMC: 9055912. DOI: 10.1111/cpr.13202. View

18.

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

19.

Chen H, Li C, Peng X, Zhou Z, Weinstein J, Liang H . A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples. Cell. 2018; 173(2):386-399.e12. PMC: 5890960. DOI: 10.1016/j.cell.2018.03.027. View

20.

Li J, Gan J, Chen C, Yuan Y, Xiong X, Li L . Downregulation of enhancer RNA AC003092.1 is associated with poor prognosis in kidney renal clear cell carcinoma. Sci Rep. 2024; 14(1):13475. PMC: 11169679. DOI: 10.1038/s41598-024-64431-8. View